AzerbaijanTuberculosis profile
Population  2015 9.8 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.038 (0.035–0.042) 0.39 (0.36–0.43)
Mortality (HIV+TB only) 0.02 (<0.01–0.055) 0.21 (0.03–0.56)
Incidence  (includes HIV+TB) 6.8 (5.5–8.1) 69 (57–83)
Incidence (HIV+TB only) 0.11 (0.07–0.16) 1.1 (0.72–1.6)
Incidence (MDR/RR-TB)** 2.5 (2–3) 26 (21–31)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.24 (0.098–0.39) 1.9 (1–2.7) 2.1 (1.1–3.1)
Males 0.36 (0.24–0.49) 4.3 (3.3–5.3) 4.7 (3.6–5.8)
Total 0.61 (0.44–0.78) 6.2 (5.4–6.9) 6.8 (5.5–8.1)
TB case notifications, 2015  
Total cases notified 7 501
Total new and relapse 5 456
          - % tested with rapid diagnostics at time of diagnosis 43%
          - % with known HIV status 128%
          - % pulmonary 80%
          - % bacteriologically confirmed among pulmonary 60%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 81% (67–98)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.01 (0–0.01)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 112 2%
          - on antiretroviral therapy 89 79%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  1 400
(1 100–1 600)
Estimated % of TB cases with MDR/RR-TB 13% (10–16) 29% (23–35)  
% notified tested for rifampicin resistance 32% 68% 3 687
MDR/RR-TB cases tested for resistance to second-line drugs   676
Laboratory-confirmed cases MDR/RR-TB: 1 171, XDR-TB: 109
Patients started on treatment **** MDR/RR-TB: 827, XDR-TB: 95
Treatment success rate and cohort size Success Cohort
New cases registered in 2014 83% 1 623
Previously treated cases registered in 2014 74% 2 374
HIV-positive TB cases, all types, registered in 2014    
MDR/RR-TB cases started on second-line treatment in 2013 59% 647
XDR-TB cases started on second-line treatment in 2013 26% 95
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment 33%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (85–100)
TB financing, 2016  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New cases
   Previously treated cases
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-09-25 Data: www.who.int/tb/data